Analysts are quick to pan Eli Lilly's puzzling first cut of positive clinical data for its Covid-19 antibody
Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.
The pharma giant reported that LY-CoV555, developed in collaboration with AbCellera, significantly reduced the rate of hospitalization among patients who were treated with the antibody. The drug arm of the study had a 1.7% hospitalization rate, compared to 6% in the control group, marking a 72% drop in risk.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.